VIATRIS INC. Other Significant Noncash Transaction, Value of Consideration Given
VIATRIS INC. (VTRS) reported Other Significant Noncash Transaction, Value of Consideration Given of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2023-02-27
- VIATRIS INC. other significant noncash transaction, value of consideration given for fiscal 2022 was $0.00.
- VIATRIS INC. other significant noncash transaction, value of consideration given for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- VIATRIS INC. other significant noncash transaction, value of consideration given for fiscal 2020 was $10.73B.
- VIATRIS INC. other significant noncash transaction, value of consideration given for fiscal 2019 was $0.00.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2020-12-31 | $10.73B 10-K · filed 2023-02-27 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |